scispace - formally typeset
Search or ask a question
Author

Yan Lin

Cardiovascular Institute of the South
Bio: Yan Lin is an academic researcher from Cardiovascular Institute of the South. The author has contributed to research in topics: Tirofiban & Percutaneous coronary intervention. The author has co-authored 1 publications.
Topics: Tirofiban, Percutaneous coronary intervention, Mace, Myocardial infarction
Papers
More filters
Journal Article•DOI•
Effect of GP IIb/IIIa inhibitor duration on the clinical prognosis of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction with no-/slow-reflow phenomenon.

[...]

Xiangming Hu1, Weimian Wang1, Jingguang Ye, Yan Lin2, Bingyan Yu3, Langping Zhou2, Yingling Zhou2, Haojian Dong2 •
Southern Medical University1, Cardiovascular Institute of the South2, South China University of Technology3
21 Sep 2021-Biomedicine & Pharmacotherapy
TL;DR: In this paper, the authors compared the efficacy and safety of short and long-term GP IIb/IIIa infusion in STEMI patients with the no/slow-reflow phenomenon.

2 citations

Cited by
More filters
Journal Article•DOI•
Efficacy and safety of intracoronary versus intravenous tirofiban in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A meta-analysis of randomized controlled trials

[...]

Rui Tian, Rugang Liu, Jiajun Zhang, Yong Li, Shujian Wei, Feng Xu, Xiaoxing Li, Chuan-Bao Li 
28 Apr 2023-Heliyon
TL;DR: In this paper , the authors compared IC and IV tirofiban in patients with ST-segment elevation myocardial infarction (STEMI) and receiving primary percutaneous coronary interventions (PPCI).
Journal Article•DOI•
Aspirin/tirofiban

[...]

01 Oct 2022-Reactions Weekly